Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

MHRA approves Merck's Winrevair (sotatercept) for adults with PAH to enhance exercise capacity and reduce functional limitations. A 24-week study showed sotatercept improved 6-minute walking ...

Designed to address the underlying causes of PAH, which involves high blood pressure in the pulmonary arteries that can lead ...

MSD acquired the therapy from Acceleron Pharma. Credit ... sotatercept operates by easing the narrowing of these arteries, helping the heart pump blood more efficiently to the lungs and improving ...

Shares in Acceleron have been grown by the third in the last month, and closed on Friday at almost $168, not far off its 52-week high of $174. Image Phil Taylor ...